BioWorld Asia

Sep. 25, 2002

KS Biomedix, Nycomed Sign Deal For TransMID 107 Cancer Therapy

LONDON - KS Biomedix Holdings plc agreed to a licensing deal worth up to US$60 million for its TransMID 107 brain cancer treatment with Nycomed Group. (BioWorld International) Read More

Neuro3d Raises EUR20M Privately To Fund Work In CNS Disorders

BCLC Says BRCA1 Increases Risk Of Other Cancers In Women

Modex, IsoTis Plan To Merge Programs In Orthopedics, Skin

EU Urges Use Of Biotechnology In And From Developing World

European Parliament Aims To Tighten GM Trade Rules

Eirx Pharma Formed Through Three-Way Anglo-Irish Merger

Cardion Closes EUR10M Financing To Fund CRB-15, Stem Cell Work

Acambis Completes Manufacture Of First Batch Of Smallpox Vaccine

Zentaris, Access Oncology Enter $30M Alliance For Cancer Drug

Other News To Note

Genset Shareholders Accept Bid From Serono; Integration Begins

Today's news in brief

BioWorld

BioWorld briefs for July 1, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 30, 2026

Illustration demonstrating gut-brain axis

CINP 2026: Gut microbiota could predict antidepressant response

BioWorld

The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...

Ascending BCI systems deepen national security, ethical concerns

BioWorld

Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...

Black wavy lines forming an abstract sound wave.png

Deep brain stimulation from the shallows: tomorrow’s BCI technology?

BioWorld

Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...